v3.25.4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:        
Research and development $ 53,140 $ 48,004 $ 168,860 $ 135,472
Selling, general and administrative 18,728 18,015 77,721 46,827
Total operating expenses 71,868 66,019 246,581 182,299
Loss from operations (71,868) (66,019) (246,581) (182,299)
Other income (expense):        
Research and development incentives 341 376 1,138 1,222
Investment income 2,846 5,137 11,256 15,243
Interest expense on finance lease liability (514) (528) (1,553) (1,594)
Interest expense on debt obligations (1,466) (1,450) (4,429) (4,314)
Other (expense) income, net (580) (3,281) (865) (850)
Total other income (expense), net 627 254 5,547 9,707
Loss before income taxes (71,241) (65,765) (241,034) (172,592)
Income tax (benefit) provision (311) 575 (311) 575
Net loss $ (70,930) $ (66,340) $ (240,723) $ (173,167)
Net loss per common share, basic (in dollars per share) $ (0.77) $ (0.79) $ (2.62) $ (2.25)
Net loss per common share, diluted (in dollars per share) $ (0.77) $ (0.79) $ (2.62) $ (2.25)
Weighted average common shares outstanding, basic (in shares) 92,187,581 83,498,892 91,874,481 77,113,695
Weighted average common shares outstanding, diluted (in shares) 92,187,581 83,498,892 91,874,481 77,113,695